Ronald Elgersma
Project Manager Byondis
Seminars
Tuesday 4th November 2025
Showcasing Preclinical Development of Byondis’ Antifolate Linker-Drug ADCs
11:00 am
- Presenting development of a novel antifolate linker-drug platform, a toxin class with a clinically validated mechanism of action
- Discussing preclinical development of antifolate-based ADCs across in vitro and in vivo studies
- Outlining antifolate payload mechanism of action and physicochemical properties
